# Evozyne

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evozyne

- Industry: Biotechnology
- Headquarters: Chicago, US
- Website: www.evozyne.com
- Total disclosed funding: $41M
- Latest round: Series B (Sep 27, 2023)
- Investors on record: 5

## About

Based in Illinois, US, and founded in 2020 by co-founders Rama Ranganathan, and Andrew Ferguson, Evozyne, Inc. operates as a biotechnology company, that offers protein-based solutions designed to address challenges and drive sustainable solutions across various sectors. In September 2023, Evozyne raised USD 81 million in series A funding co-led by OrbiMed Advisors and Fidelity Management and Research Company, with participation from NVentures. Returning investors Paragon Biosciences LLC and Valor Equity Partners also participated in the round. As of September 2023, the company is led by its CEO Mike Gamson.   

Evozyne, Inc.'s core product is the development of novel therapeutics such as IgG Protease, CRISPR, and carbon capture with performance characteristics. These proteins have broad applications in various industries, including therapeutics and sustainability. By leveraging Evozyne's protein engineering technology, these products offer solutions for advancements in areas such as drug development, sustainable energy, and environmental conservation.

The company plans to use the series A funding to advance its generative AI-powered drug discovery platform and product development.

## Funding rounds

- Series B, Sep 27, 2023, $41M — OrbiMed Advisors, Valor Equity Partners, Fidelity Management and Research Company, Paragon Biosciences LLC, NVentures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Valor Equity Partners (https://capitalatlas.ai/funds/valor-equity-partners) — Series B
- Fidelity Management and Research Company — Series B
- Paragon Biosciences LLC — Series B
- NVentures — Series B